LEARNING OBJECTIVES

At end of this session, learners will be able to:
 

KP Excellence in Cancer Care Leadership

• Describe the Importance of our cancer outcomes and ways to improve them

Optimizing the Management and Outcomes for Cancer Survivors Transitioning to Follow-up Care
 

• Understand the principles of quality cancer survivorship care and the roles of primary care and oncology providers
• List examples of available educational tools/resources in cancer survivorship
• Plan actionable steps to apply learnings to clinical practice
   

Survivorship Pilot

• Identify national trends in cancer survivorship
• Understand issues in access and quality of care for cancer survivors
• Gain insight into different models of survivorship care
• Understand current survivorship research including a KPSC clinical trial for breast and colorectal cancer survivors
   

Primary Care’s Role (in Cancer)

• Demonstrate real-world experiences of primary care physicians (PCPs) in caring for cancer survivors
• Using case studies, gain understanding of what types of patients thrive when paired with a trained survivorship PCP
   

Survivorship Digital Platform

• Describe and utilize the opportunities available to help engage and empower our members / patients through survivorship
• Describe the benefits of the survivorship digital platform
   

Robotic Surgery in Cancer

• Describe the principles of robot assisted laparoscopic surgery, including the benefits to the patients, as well as be comfortable with the safety and oncologic applications of this advanced surgical technique
• Describe both the benefits as well as limitations of this surgical platform to the cancer patient with regards to oncologic outcomes and cost-effectiveness
   

Rectal Cancer Staging and Transanal Approaches to Polyps and Early Stage Cancers
 

• Identify the pros and cons of rectal cancer staging modalities
• Apply transanal approaches to polyps and early stage cancers
   

Watch and Wait for Patients with cCR after TNT for Rectal Cancer
 

• Identify complete clinical response (cCR)
• Identify any changes or lack thereof in survivorship screening in patients with complete clinical response (cCR)
• Know who should be performing watch and wait (i.e., the surgeon), which is the alternative to surgery
   

TNT Approaches for Rectal Cancer

• Describe Short-Course vs. Long-Course RT
• Apply optimal Sequencing of RT and Chemo
• Employ the optimal TNT regimen
   

Unusual Blood Clots (Plus 22 Teaching Points about ‘Usual’ Blood Clots)
 

• Use a systematic approach when evaluating a patient with a thrombosis in an unusual location and deciding on best anticoagulation management
• List the 3 components that determine duration of anticoagulation in patients with thrombosis in an unusual location
• Feel more comfortable/confident making treatment decisions when evaluating and treating a patient with a thrombosis in an unusual location
• Decide how long to treat a patient with cerebral and sinus vein thrombosis with anticoagulation
• Work-up a patient with retinal vascular occlusions for an underlying etiology and give antithrombotic therapy recommendations
• Make decisions on whether a patient with liver cirrhosis-associated portal vein thrombosis should be treated with anticoagulation
   

Acute Myeloid Leukemia

• Evaluate and treat high grade lymphomas and acute leukemias at centers with high volumes and a dedicated team

Sickle Cell Anemia: Updates in New Therapies, Transplant Strategies, and Gene Therapy/Trials for the AYA Population
 

• Describe current strategies in the management of severe sickle cell anemia patients
• Apply the current approaches to transplantation (BMT) for severe sickle cell anemia
• Describe the portfolio of clinical trial options and recommend operational workflows with KPSC for timely referral of adolescent and young adults with severe sickle cell anemia
   

Sarcoma in AYA

• Describe current pediatric clinical trials available for young adults and enroll patients as appropriate

Updates in Neuro Oncology

• Describe and apply new approaches to neuro oncological diseases

Internalization of Genomic Testing in SCAL

• Identify the key elements that must be met before selecting the right assay
• State the reasons why internalization of genomic testing can improve patient care
• Name some of the considerations that influence the design, validation, and interpretation of tumor molecular assays
   

Available Technology

• Name the techniques that are used to prepare NGS libraries
• Identify the different software that will be used to analyze and annotate the mutations
• Identify the 5 different testing components in this assay that will be used for cancer patient treatment
   

KP National Virtual Cancer Center: Overview & Leadership
 

• Describe how KP will operationalize tele-oncology on a national level
• Describe how KP will provide expert care for every Kaiser Permanente member across the enterprise
   

Impact of Reducing Re-Excision Rates After Breast Conserving Surgery
 

• Describe techniques which can be used to reduce rates of re-excision after breast conserving surgery
   

Mode of Detection of Second Breast Cancers in Patients Undergoing Surveillance After Treatment of Ductal Carcinoma in Situ
 

• Describe the limited role clinical breast exam plays in the detection of second breast cancers after a diagnosis of DCIS
   

Young Women and Breast Cancer

• Describe unique challenges of diagnosing and treating breast cancer in younger women

PSMA Therapeutics for Metastatic Castration Resistant Prostate Cancer
 

• Describe mechanism of action of Lu-177-PSMA-617
• Assess eligibility and potential risks and benefits of therapy with Lu-177-PSMA-617
   

Hormone Sensitive Prostate Cancer

• Describe the new data regarding triplet therapy versus doublet therapy
• Apply the above new information in the clinical application of real world cases
   

Geriatric Oncology: G8 and CARG Toxicity Score Can Predict Emergency Room (ER) Visits, Hospitalizations, and Mortality in Older Patients with Newly Diagnosed Cancer
 

• Describe the linkage between G8, CARG and chemotherapy toxicity
• Identify possible strategies for implementing geriatric assessments in a community oncology practices
   

Non-Melanoma Skin Cancer, Squamous Cell, Basal Cell, and Merkle Cell Carcinomas
 

• Apply the most recent therapeutic strategies to cases
• Describe emerging strategies in the neoadjuvant and adjuvant setting
• Discuss clinical trial findings and implications
   

Melanoma

• Discuss adoptive cell therapy
• Describe and apply novel therapeutic options for Melanoma
   

QTP Overview

• Describe how to participate in the QTP at KP

Improving Time to Molecular Testing Results in Patients with Newly Diagnosed, Metastatic Non-Small Cell Lung Cancer (NSCLC)
 

• Apply strategies to improve testing time for patients newly diagnosed with Non-Small Cell Lung Cancer (NSCLC)
   

I-DO GOC: Improving Documentation in Oncology with Goals of Care
 

• Apply strategies to improve documentation in goals of care

Management of Early Stage Lung Cancer, Neoadjuvant vs. Adjuvant Treatment
 

• Describe the role of neoadjuvant vs. adjuvant treatments in early stage lung cancer
• Describe the importance of obtaining molecular data prior to treatment of early stage disease
   

Recognizing and Managing TKI Toxicities

• Identify some drug specific TKI toxicities and apply appropriate management

National Lung Cancer Initiatives

• Describe unique challenges of diagnosing and treating breast cancer in younger women

ASCO 2022 Updates

• Describe the latest research related to Head and Neck Cancer

ePRO Use in Head and Neck Cancer – KP experience
 

• Describe how ePRO use can improve the patient experience in Head and Neck Cancer

HPV Vaccination

• Use strategies to get patients vaccinated for HPV

Clinical Trial NRG HN009

• Describe the latest research related to Head and Neck Cancer
• Use strategies to enroll more patients in clinical trials
   

NCAL HNC Multidisciplinary TB Data

• Describe the latest research related to Head and Neck Cancer
• Use strategies to improve screening for TB
   

Introduction and Brief Overview of Our Gyn Onc National Program
 

• Describe the structure and integration of the Permanente Medical Groups in the KP National Excellence in Cancer Care Program, Gynecologic Oncology program
   

Understanding Racial and Ethnic Disparities in ovarian cancer treatment and survival: The NCI-funded KP ROCS Study
 

• Describe the current status of knowledge regarding racial and ethnic disparities in ovarian cancer outcomes
• Describe the process of evaluating disparities in care for ovarian cancer within KP
• Consider a broader overview of factors that may contribute to racial and ethnic disparities in cancer outcomes
   

Cervical Cancer Screening Project (PCORI Grant)

• Apply learnings from the roll out of the largest Primary HPV screening program for cervical cancer screening to future quality initiatives
   

Streamlined Ovarian Cancer Genomic Testing in KP SF
 

• Describe the potential role for Gyn Onc led genetic testing

ACCREDITATION DESIGNATION STATEMENT

The Kaiser Permanente National CME Program is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT STATEMENT

The Kaiser Permanente National CME Program designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™ .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Physician Assistants – Attendees may report up to 14 hours toward continuing education requirements for license renewal. ‘CME’ can be written in lieu of the provider number on all licensure renewal applications.

Day 1:   7
Day 2:   7
Total:  14

TARGET AUDIENCE

• Medical oncologists, radiation oncologists, oncology nurses, oncology pharmacists, pathologists, and other staff who work in these specialty departments
• Surgical oncology and imaging physicians, nursing and care coordinators (e.g., breast surgeons, breast cancer nurses, breast imagers, and breast care coordinators)
• Researchers
• Cancer Care Administrators
• Quality

All PMG Regions